FY17 Center for Valve Disorders Clinical Team:
Mitral regurgitation happens when the heart’s mitral
valve doesn’t close tightly, allowing blood to flow
backward into the heart. For years, open heart surgery
was the only treatment option for mitral regurgitation.
In recent history and through the advanced research and
studies conducted by cardiologists on the medical staff
at Baylor Hamilton Heart and Vascular Hospital, mitral
regurgitation can be treated using devices that are placed
through a small incision in the groin. • James W. Choi, MD, FACC, FSCAI
Named in a prior fiscal year as one of the few sites
worldwide to offer Tendyne Bioprosthetic Mitral Valve
System, this trial continues to show promise in improving
patient’s stamina and greater ability for exercise capacity.
This device is helpful for patients too frail to undergo
open heart surgery. Primary investigator for this has been
Paul Grayburn, MD, Medical Director – Non-Invasive
Cardiology – Baylor Hamilton Heart and Vascular Hospital.
In addition, the multidisciplinary team is leading the
nation as one of the sites with the most volume using
the Abbott MitraClip®, approved a few years ago for
commercial availability. Cardiologists on the medical
staff at Baylor Hamilton Heart and Vascular Hospital
were involved in the original initial COAPT Trial which
led to the evolution of this device.
30-DAY VALVE READMISSION RATE*
Baylor Hamilton Heart and Vascular Hospital 0%
US Benchmark
7%
*NCDR outcomes report 12-months ending 2017 Q1;
30-day follow-up Report
TRANSCATHETER MITRAL VALVE REPAIR
• Paul A. Grayburn, MD, FACC
• Robert F. Hebeler, Jr., MD, FACS
• Albert Carl Henry, III, MD, FACS
• Stuart Lander, MD, FACC
• Brian Lima, MD
• J.C. MacHannaford, MD
• Robert C. Stoler, MD, FACC, FSCAI
• Ravi C. Vallabhan, MD, FACC, FSCAI
• Haojie Wang, MD, PhD, FACC, RPVI
• Nurse Practitioner: Maninder J. Kaur, RN, MS,
APRN, ANP-BC
• Clinical Coordinator: Paz McDonald, MSN,
CCRN, RN-BC
• Operations Manager: Jennifer Lenge, BSN,
RN-BC
• Clinical Research Coordinators
More than
600
TAVRs since 2011
2-DAY
Median Length of Stay
(FY17)
20.6% of patients were
discharged post-op day 1
TRANSCATHETER AORTIC VALVE
REPLACEMENT (TAVR) CASES
250
Volumes
200
Percent per
type
202
150
115
50
0
FY15 FY16 FY17
Transfemoral
Transapical
93%
1%
Direct Aortic 0.5%
Subclavian 1.4%
Femoral Cutdown 3.9%
138
100
43